INVA Stock Summary and Trading Ideas (Innoviva | NASDAQ:INVA)

Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Innoviva trades on the NASDAQ stock market under the symbol INVA.

As of January 16, 2026, INVA stock price declined to $19.44 with 498,720 million shares trading.

INVA has a beta of 0.03, meaning it tends to be less sensitive to market movements. INVA has a correlation of 0.00 to the broad based SPY ETF.

INVA has a market cap of $1.45 billion. This is considered a Small Cap stock.

Last quarter Innoviva reported $108 million in Revenue and $1.08 earnings per share. This beat revenue expectation by $15 million and exceeded earnings estimates by $.66.

In the last 3 years, INVA traded as high as $22.76 and as low as $10.64.

The top ETF exchange traded funds that INVA belongs to (by Net Assets): IJR, VTI, AVUV, VB, IWM.

INVA has underperformed the market in the last year with a price return of +5.4% while the SPY ETF gained +18.1%. However, in the short term, INVA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.7% vs +5.0% return in SPY. But in the last 2 weeks, INVA shares have been beat by the market, returning -2.2% compared to an SPY return of +1.2%.

INVA support price is $19.44 and resistance is $20.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INVA shares will trade within this expected range on the day.